Stephen Davis - Oct 5, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: CEO, Director
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Stock symbol: ACAD
Transactions as of: Oct 5, 2023
Transactions value $: -$1,132,323
Form type: 4
Date filed: 10/6/2023, 09:59 PM
Previous filing: Jul 18, 2023
Next filing: Jan 9, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+104K	+283.41%		141K	Oct 5, 2023	Direct	F1, F2
transaction	ACAD	Common Stock	Sale	-$1.13M	-51.6K	-36.65%	$21.96	89.1K	Oct 6, 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-104K	-37.5%	$0.00	173K	Oct 6, 2023	Common Stock	104K		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2	Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023.
F3	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4	Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.